sRANK Ligand Antibody

Contact us
ProSci
Product Code: PSI-3963
Product Group: Primary Antibodies
Supplier: ProSci
CodeSizePrice
PSI-3963-0.02mg0.02mg£150.00
Quantity:
PSI-3963-0.1mg0.1mg£449.00
Quantity:
Prices exclude any Taxes / VAT

Overview

Host Type: Rabbit
Antibody Isotype: IgG
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Applications:
  • Enzyme-Linked Immunosorbent Assay (ELISA)
  • Immunohistochemistry (IHC)
  • Western Blot (WB)

Images

1 / 6
<strong>Figure 1 Western Blot Validation in Human Cell Lines </strong><br> Loading: 15 μg of lysates per lane. Antibodies: sRANK-L 3963 (1 μg/mL), 1h incubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.
2 / 6
<strong>Figure 1 Western Blot Validation in Mouse Tissues</strong><br> Loading: 15 μg of lysates per lane. Antibodies: sRANK-L 3963 (2 μg/mL), 1h incubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.
3 / 6
<strong>Figure 3 Western Blot Validation with Recombinant Protein</strong><br> Loading: 30 ng of human sRANK-L recombinant protein per lane. Antibodies: sRANK-L 3963 (A: 1 μg/mL, B: 2 μg/mL and C: 4 μg/mL), 1h incubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution. Observed at around 27kD.
4 / 6
<strong>Figure 4 Western Blot Validation in Rat Liver Tissue</strong><br> Loading: 15 μg of lysates per lane. Antibodies: sRANK-L 3963 (A: 0.25 μg/mL and B: 0.5 μg/mL), 1h incubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.
5 / 6
<strong>Figure 5 Immunohistochemistry Validation of sRANK-L in Human Liver Tissue </strong><br> Immunohistochemical analysis of paraffin-embedded human liver tissue using anti sRANK-L antibody (3963) at 5 μg/ml. Tissue was fixed with formaldehyde and blocked with 10% serum for 1 h at RT; antigen retrieval was by heat mediation with a citrate buffer (pH6). Samples were incubated with primary antibody overnight at 4˚ C. A goat anti-rabbit IgG H&L (HRP) at 1/250 was used as secondary. Counter stained with Hematoxylin.
6 / 6
<strong>Figure 6 Immunohistochemistry and Induced Expression Validation of sRANK-L in Rat Osteogenic Compartment (Hassan et al., 2017) </strong><br> Protein analysis for sRANK-L by immunohistochemistry with anti-sRANK-L antibodies (3963) in rat osteogenic cells. Strong immunoreactivity is shown for sRANK-L in osteogenic cells at 18hr after upper jaw molar extraction as compared to baseline.
❮❯

<strong>Figure 1 Western Blot Validation in Human Cell Lines </strong><br> Loading: 15 μg of lysates per lane. Antibodies: sRANK-L 3963 (1 μg/mL), 1h incubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.
<strong>Figure 1 Western Blot Validation in Mouse Tissues</strong><br> Loading: 15 μg of lysates per lane. Antibodies: sRANK-L 3963 (2 μg/mL), 1h incubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.
<strong>Figure 3 Western Blot Validation with Recombinant Protein</strong><br> Loading: 30 ng of human sRANK-L recombinant protein per lane. Antibodies: sRANK-L 3963 (A: 1 μg/mL, B: 2 μg/mL and C: 4 μg/mL), 1h incubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution. Observed at around 27kD.
<strong>Figure 4 Western Blot Validation in Rat Liver Tissue</strong><br> Loading: 15 μg of lysates per lane. Antibodies: sRANK-L 3963 (A: 0.25 μg/mL and B: 0.5 μg/mL), 1h incubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.
<strong>Figure 5 Immunohistochemistry Validation of sRANK-L in Human Liver Tissue </strong><br> Immunohistochemical analysis of paraffin-embedded human liver tissue using anti sRANK-L antibody (3963) at 5 μg/ml. Tissue was fixed with formaldehyde and blocked with 10% serum for 1 h at RT; antigen retrieval was by heat mediation with a citrate buffer (pH6). Samples were incubated with primary antibody overnight at 4˚ C. A goat anti-rabbit IgG H&L (HRP) at 1/250 was used as secondary. Counter stained with Hematoxylin.
<strong>Figure 6 Immunohistochemistry and Induced Expression Validation of sRANK-L in Rat Osteogenic Compartment (Hassan et al., 2017) </strong><br> Protein analysis for sRANK-L by immunohistochemistry with anti-sRANK-L antibodies (3963) in rat osteogenic cells. Strong immunoreactivity is shown for sRANK-L in osteogenic cells at 18hr after upper jaw molar extraction as compared to baseline.

Documents

Further Information

Additional Names:
sRANK Ligand Antibody: ODF, OPGL, sOdf, CD254, OPTB2, RANKL, TRANCE, hRANKL2, Tumor necrosis factor ligand superfamily member 11, Osteoclast differentiation factor, ODF
Application Note:
WB: 0.25-4 μg/mL; IHC: 5 μg/mL.

Antibody validated: Western Blot in human, mouse and rat samples; Immunohistochemistry in human and rat samples. All other applications and species not yet tested.
Background:
sRANK Ligand Antibody: The receptor activator of NF-κB ligand (RANK-L) is a recently discovered member of the TNF-ligand family involved in the regulation of the T cell-dependent immune response, lymph node organogenesis and bone formation. RANK-L exists as both a normal, transmembrane form and a truncated, soluble form (sRANK-L), both of which can stimulate the receptor. Activation of T cells, such as by treatment with interleukin-7, induces RANK-L production and leads to an increase of osteoclast formation and bone loss. Finally, sRANK-L can activate the antiapoptotic kinase Akt through a signaling complex involving Src kinase and TRAF6, suggesting sRANK-L may also play a role in regulating apoptosis. This antibody will recognize both the soluble form and the uncleaved transmembrane form of RANK-L.
Background References:
  • Wong, et al. J. Biol. Chem. 1997; 272:25190-4.
  • Kong et al. Nature 1999; 397:315-23.
  • Weitzmann et al. Blood 2000; 96:1873-8.
  • Bharti et al. J. Biol. Chem. 2004; 279:6065-76.
Buffer:
sRANK Ligand Antibody is supplied in PBS containing 0.02% sodium azide.
Concentration:
1 mg/mL
Conjugate:
Unconjugated
DISCLAIMER:
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
Immunogen:
Anti-sRANK-L antibody (3963) was raised against a peptide corresponding to 14 amino acids near the center of human sRANK-L.

The immunogen is located within amino acids 140-190 of sRANK-L.
ISOFORMS:
Human sRANK-L has 3 isoforms, including isoform 1 (317aa, 35.5kD), isoform 2 (244aa, 27.7kD) and isoform 3 (270aa, 30.5kD). Mouse sRANK-L also has 3 isoforms, including isoform 1 (316aa, 35kD), isoform 2 (287aa, 32.3kD) and isoform 3 (199aa, 22.2kD). Rat sRANK-L has one isoform (318aa, 38.4kD). 3963 can detect human, mouse and rat.
NCBI Gene ID #:
8600
NCBI Official Name:
tumor necrosis factor (ligand) superfamily, member 11
NCBI Official Symbol:
TNFSF11
NCBI Organism:
Homo sapiens
Physical State:
Liquid
PREDICTED MOLECULAR WEIGHT:
Predicted: 36kD

Observed: 36 kD
Protein Accession #:
NP_003692
Protein GI Number:
4507595
Purification:
sRANK Ligand Antibody is affinity chromatography purified via peptide column.
Research Area:
Apoptosis
Swissprot #:
O14788
User NOte:
Optimal dilutions for each application to be determined by the researcher.
VALIDATION:

Recombinant Protein Test (Figure 3): Anti-sRANK-L antibodies (3963) detected human sRANK-L recombinant protein at different concentrations.

Induced expression validation (Figure 6): sRANK-L expression detected by anit-sRANK-L antibodies (3963) was up-regulated after 18hr by extraction of  upper jaw molars in rat osteogenic cells.

References

  1. Hassan et al. Coordination of early cellular reactions during activation of bone resorption in the rat mandible periosteum: An immunohistochemical study. Heliyon. 2017;3(10):e00430. PMID: PMID: 29226261.

Related Products

Product NameProduct CodeSupplier 
sRANK-L PeptidePSI-3963PProSci Summary Details